Bausch & Lomb Corp (BLCO) Stock Price, Quote & News

Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeut...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 905 695 7700

Website: www.bausch.com

Address:

520 Applewood Crescent, Vaughan, Canada

Rpate Feb. 20 at 5:24 PM

$BLCO After IPO this is first time company has shown positive free cash flow for two consecutive quarter.

0 · Reply

Sciguy67 Feb. 20 at 5:09 PM

$BLCO sold by 2027

0 · Reply

erevnon Feb. 19 at 4:27 PM

Wells Fargo maintains Bausch & Lomb $BLCO at Equal-Weight and raises the price target from $17 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Angiesix Feb. 19 at 12:59 PM

$BHC $BLCO Remember once $BHC gets below the 6.5x leverage ratio (7.2x to 7.5x now) and or they win the ongoing lawsuit against its lenders, they are free of the lenders (of which JANA partners is now also at the table) because they also bought the debt, to deal with monetizing $BLCO - It's not an if, it's a when. The debt contracts prohibit the above at 6.5x leverage ratio. Until then lenders have tied the hands of management.

1 · Reply

FrancesSimmonsa Feb. 19 at 2:17 AM

$VWAV VisionWave Enters into $10 Million Statement of Work for Development of qSpeed-Mine™ - Mining Acceleration Platform. https://www.stocktitan.net/news/VWAV/vision-wave-enters-into-10-million-statement-of-work-for-development-65jjzbwxrbli.html $EBAY $BA $BLCO $WMT

0 · Reply

SellSalix Feb. 19 at 1:57 AM

$BHC $BHC this earnings call finally proves what I’ve known for some time now; that we have here is a Leap; a long dated call option on $BLCO . If BLCO gets to $30 or more, this POS will fly, and I’m talking multi-bagger. If it doesn’t get close to $30 by then, this POS is toast! Good news is we have until 2028, but we need BLCO to perform extremely well for the next couple of years; and Xifaxan needs to remain exclusive until then. And, the bad news, we’ll have to continue to wait for while longer. Personally, I am thinking of realizing a loss on this but will continue to hold my calls.

0 · Reply

Estimize Feb. 19 at 1:39 AM

$BLCO reported 0.32 EPS and 1,405 revenue for Q4. http://www.estimize.com/intro/blco?chart=historical&metric_name=eps&utm_content=BLCO&utm_

0 · Reply

TickrTalk0007 Feb. 19 at 1:29 AM

$BLCO short it all the way to ZERO…

0 · Reply

Angiesix Feb. 18 at 9:05 PM

$BHC Don't be so negative. JANA Partners is trying here. Let's sell a bit to retire debt, distribute 80% of $BLCO to $BHC shareholders. $COO split (Coopervision) merging with $BLCO is the ultimate goal. Each $1 bln debt retired is approx. $2.70 to $BHC share price.

1 · Reply

Rpate Feb. 18 at 5:55 PM

$BLCO is diluting equity very rapidly issuing bonuses and RSU to employees. In 2026 it would be 364 M.

1 · Reply

Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®

Feb 18, 2026, 12:55 PM EST - 7 days ago

Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call Transcript

Feb 18, 2026, 6:58 AM EST - 8 days ago

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

Jan 20, 2026, 7:15 AM EST - 5 weeks ago

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18

Jan 12, 2026, 6:06 PM EST - 6 weeks ago

Bausch + Lomb Corporation (BLCO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 5, 2026, 7:00 AM EST - 7 weeks ago

Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.

Jan 2, 2026, 4:30 PM EST - 7 weeks ago

Bausch + Lomb Completes Refinancing of Outstanding Term B Loans

Dec 23, 2025, 7:30 AM EST - 2 months ago

Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 4:30 PM EST - 2 months ago

Bausch + Lomb Announces Two Board of Directors Appointments

Dec 12, 2025, 4:48 PM EST - 2 months ago

Bausch + Lomb Announces Refinancing of Outstanding Term B Loans

Dec 3, 2025, 12:43 PM EST - 3 months ago

Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 18, 2025, 4:30 PM EST - 3 months ago

Bausch + Lomb to Participate in Citi Global Healthcare Conference

Nov 17, 2025, 7:57 PM EST - 3 months ago

Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation - Analyst/Investor Day Transcript

Nov 10, 2025, 6:59 AM EST - 3 months ago

Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program

Oct 29, 2025, 2:26 PM EDT - 4 months ago

Bausch + Lomb Corporation (BLCO) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 6:58 AM EDT - 4 months ago

Bausch + Lomb Announces Third-Quarter 2025 Results

Oct 19, 2025, 8:00 PM EDT - 4 months ago

Activist Jana Takes Stake in Cooper, a Maker of Medical Devices

COO

Sep 29, 2025, 7:15 AM EDT - 5 months ago

Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13

Sep 8, 2025, 2:37 PM EDT - 6 months ago

Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 7:00 AM EDT - 6 months ago

Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States

Aug 18, 2025, 5:01 PM EDT - 6 months ago

Bausch + Lomb Announces Board Changes

Aug 14, 2025, 7:15 AM EDT - 7 months ago

Bausch + Lomb to Participate in Upcoming Investor Conferences

Jul 30, 2025, 9:33 PM EDT - 7 months ago

Bausch + Lomb Corporation (BLCO) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 6:57 AM EDT - 7 months ago

Bausch + Lomb Announces Second-Quarter 2025 Results

Jul 1, 2025, 7:00 AM EDT - 8 months ago

Bausch + Lomb Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions about Dry Eye

Jun 30, 2025, 6:58 AM EDT - 8 months ago

Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13

Jun 18, 2025, 4:30 PM EDT - 9 months ago

Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering

Jun 17, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Bausch + Lomb Corporation (BLCO) And Encourages Investors to Connect

Jun 16, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Bausch + Lomb Corporation (BLCO) Stockholders to Inquire about Securities Investigation

Jun 15, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bausch + Lomb Corporation (BLCO) and Encourages Investors to Learn More About the Investigation

Jun 13, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bausch + Lomb Corporation (BLCO) And Encourages Investors to Reach Out

Jun 12, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bausch + Lomb Corporation (BLCO) And Encourages Stockholders to Reach Out

Jun 11, 2025, 10:02 AM EDT - 9 months ago

BLCO Investors Have Opportunity to Join Bausch + Lomb Corporation Fraud Investigation with the Schall Law Firm

Jun 11, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Bausch + Lomb Corporation (BLCO) And Encourages Stockholders to Connect

Jun 10, 2025, 10:00 AM EDT - 9 months ago

Bausch + Lomb Corporation (BLCO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jun 10, 2025, 8:48 AM EDT - 9 months ago

Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement

Jun 9, 2025, 12:00 PM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bausch + Lomb Corporation (BLCO) and Encourages Stockholders to Learn More About the Investigation

May 22, 2025, 7:30 AM EDT - 10 months ago

Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference

May 21, 2025, 4:30 PM EDT - 10 months ago

Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

Apr 30, 2025, 11:02 AM EDT - 10 months ago

Bausch + Lomb Corporation (BLCO) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 6:57 AM EDT - 10 months ago

Bausch + Lomb Announces First-Quarter 2025 Results

Apr 24, 2025, 7:00 AM EDT - 11 months ago

Bausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall

Apr 11, 2025, 10:00 AM EDT - 11 months ago

Bausch + Lomb (BLCO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 10, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Bausch + Lomb (BLCO) Shareholders to Inquire about Securities Investigation

Apr 9, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Bausch + Lomb (BLCO) And Encourages Shareholders to Connect

Apr 8, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bausch + Lomb (BLCO) And Encourages Shareholders to Reach Out

Rpate Feb. 20 at 5:24 PM

$BLCO After IPO this is first time company has shown positive free cash flow for two consecutive quarter.

0 · Reply

Sciguy67 Feb. 20 at 5:09 PM

$BLCO sold by 2027

0 · Reply

erevnon Feb. 19 at 4:27 PM

Wells Fargo maintains Bausch & Lomb $BLCO at Equal-Weight and raises the price target from $17 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Angiesix Feb. 19 at 12:59 PM

1 · Reply

FrancesSimmonsa Feb. 19 at 2:17 AM

0 · Reply

SellSalix Feb. 19 at 1:57 AM

0 · Reply

Estimize Feb. 19 at 1:39 AM

$BLCO reported 0.32 EPS and 1,405 revenue for Q4. http://www.estimize.com/intro/blco?chart=historical&metric_name=eps&utm_content=BLCO&utm_

0 · Reply

TickrTalk0007 Feb. 19 at 1:29 AM

$BLCO short it all the way to ZERO…

0 · Reply

Angiesix Feb. 18 at 9:05 PM

1 · Reply

Rpate Feb. 18 at 5:55 PM

$BLCO is diluting equity very rapidly issuing bonuses and RSU to employees. In 2026 it would be 364 M.

1 · Reply

StocktwitsEarnings Feb. 18 at 2:14 PM

$BLCO Q4 '25 Earnings Results & Recap Bausch + Lomb provided 2026 full-year revenue guidance between $5.38B and $5.48B, representing 5% to 7% constant currency growth. The company also expects full-year Adjusted EBITDA excluding Acquired IPR&D to be $1B to $1.05B.

0 · Reply

OpenOutcrier Feb. 18 at 1:36 PM

$BLCO (-3.2% pre) Bausch + Lomb earnings miss as revenue tops estimates https://ooc.bz/l/93695

0 · Reply

Contrarian_Dan Feb. 17 at 9:47 PM

$BLCO buy offer coming?!

2 · Reply

TickrTalk0007 Feb. 12 at 1:48 PM

$BLCO is stale....bad BD deals, low revenues and no blockbuster drug.

0 · Reply

BillionerOfKing Feb. 11 at 1:56 PM

$BLCO Current Stock Price: $17.14 Contracts to trade: $17.0 BLCO Feb 20 2026 Call Entry: $0.72 Exit: $0.93 ROI: 29% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

SuperGreenToday Feb. 11 at 12:22 AM

$BLCO

0 · Reply

vcd103 Feb. 8 at 4:07 AM

$BHC Crazy to look at stock performance over last 5 years or so.. Papa's turnaround of lifettime was a joke and now until $BLCO value picks up a bit, this will languish for many more years. https://stocktwits.com/symbol/BHC?utm_source=android_app&utm_medium=symbol_share&utm_campaign=symbol_page_sharing

0 · Reply

TickrTalk0007 Jan. 29 at 1:59 PM

$BLCO B&L is a disaster....Brent's strategy not playing out with early stage pipeline....no billion dollar sales potential drugs....Meibo can be bought in Europe for $20. Why is US healthcare system paying $700 for it?

0 · Reply

AKTN Jan. 26 at 5:55 PM

$BHC the only way this is going up is canning the entire fkin' management team and put it back together with $BLCO and put Saunders in the captain's chair. What good is BAUSH Health companies without BAUSCH and Lomb?? Opportunity cost of a lifetime.

4 · Reply

AKTN Jan. 23 at 6:19 PM

$BHC $BLCO MERGE THESE TWO POS BACK TOGETHER. Dumbest idea ever from the decaying mind of old fat Joe.

1 · Reply

SuperGreenToday Jan. 23 at 5:35 AM

$BLCO Share Price: $17.17 Contract Selected: Dec 18, 2026 $15 Calls Buy Zone: $1.70 – $2.10 Target Zone: $2.78 – $3.39 Potential Upside: 54% ROI Time to Expiration: 329 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

kbingo12 Jan. 12 at 3:43 PM

$BLCO https://aflegal.org/press-release/america-first-legal-files-lawsuit-against-bausch-lomb-for-racial-discrimination-in-board-appointments/

1 · Reply

Market Cap	6.53B
Revenue (ttm)	5.10B
Net Income (ttm)	-360.00M
EPS (ttm)	N/A
PE Ratio	35.98
Forward PE	22.71
Profit Margin	-7.06%
Debt to Equity Ratio	0.78

Volume	406,900
Avg Vol	380,142
Day's Range	N/A - N/A
Shares Out	354.29M
Stochastic %K	88%
Beta	0.61
Analysts	Sell
Price Target	$18.69